指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

国家银屑病基金会COVID-19工作组银屑病管理指导第2版:银屑病管理、COVID-19疫苗与治疗的进展

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
指南 / 共识 · J Am Acad Dermatol · 2021-01-07
一句话结论国家银屑病基金会工作组以德尔菲法更新银屑病COVID-19管理指导,涵盖疾病及治疗对COVID-19风险的影响、疫情期间医疗优化、感染预防(含新型疫苗接种)及感染后处理。

该指导由国家银屑病基金会COVID-19工作组制定,工作组含18名投票委员,专长涵盖皮肤科、风湿科、流行病学、感染病和重症医学,另有非投票成员。工作组就银屑病患者在疫情期间的管理问题开展德尔菲流程,更新了原有22条声明的证据并新增5条推荐。所有声明投票均值均落在同意类别内,其中13条高度共识、14条中度共识。声明为银屑病患者治疗提供指导,涉及疾病及治疗如何影响COVID-19风险、疫情期间如何优化医疗、患者如何降低感染严重急性呼吸综合征冠状病毒2(包括新型疫苗接种)的风险以及感染COVID-19后如何处理。该指导为活文件,由工作组随数据出现持续更新。

要点

  • 工作组更新原有22条声明的证据并新增5条推荐,所有声明投票均值均落在同意类别内。
  • 13条声明为高度共识,14条声明为中度共识。
  • 声明涵盖银屑病及其治疗如何影响COVID-19风险。
  • 声明涵盖疫情期间如何优化医疗、患者如何降低感染严重急性呼吸综合征冠状病毒2的风险(包括新型疫苗接种)。
  • 声明涵盖患者感染COVID-19后应如何处理,该指导为活文件并随数据出现持续更新。

适用人群与场景

  • 银屑病患者,涉及疾病及治疗对COVID-19风险的影响、疫情期间医疗优化、感染预防及感染后处理。

研究设计与关键结果

  • 工作组含18名投票委员,专长涵盖皮肤科、风湿科、流行病学、感染病和重症医学,另有非投票成员(包括研究员和国家银屑病基金会工作人员)。
  • 临床问题来源于国家银屑病基金会收到的咨询,采用德尔菲流程。
  • 工作组更新原有22条声明的证据并新增5条推荐;所有声明投票均值落在同意类别内,13条高度共识、14条中度共识。

证据类型、等级与局限

  • 证据类型:基于德尔菲流程的指导声明。
  • 局限:原文报告许多指导声明背后的证据质量或数量不一。

对床旁实践的改变

  • 声明为银屑病患者治疗提供指导,主题包括疾病及治疗如何影响COVID-19风险、疫情期间如何优化医疗、患者如何降低感染严重急性呼吸综合征冠状病毒2的风险(包括新型疫苗接种)以及感染COVID-19后如何处理。
  • 该指导为活文件,由工作组随数据出现持续更新。

指南或共识出处

  • 国家银屑病基金会COVID-19工作组指导第2版(National Psoriasis Foundation COVID-19 Task Force guidance),国家银屑病基金会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.

STUDY DESIGN: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.

RESULTS: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.

LIMITATIONS: The evidence behind many guidance statements is variable in quality and/or quantity.

CONCLUSIONS: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

参考来源

  1. Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021. PMID: 33422626. doi:10.1016/j.jaad.2020.12.058

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。